相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients
Lihua Yu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)
GD2-CART cell therapy for H3K27M-mutated diffuse midline gliomas
Robbie G. Majzner et al.
NATURE (2022)
Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives
Nora Berois et al.
CANCERS (2022)
The regulatory role of autophagy-related miRNAs in lung cancer drug resistance
Mahshid Shahverdi et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction
Amirhossein Mardi et al.
CANCER CELL INTERNATIONAL (2022)
Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells
Peng-Fei Zhang et al.
IMMUNOTHERAPY (2022)
Cancer combination therapies by silencing of CTLA-4, PD-L1, and TIM3 in osteosarcoma
Amin Daei Sorkhabi et al.
IUBMB LIFE (2022)
Exhaustion of CAR T cells: potential causes and solutions
Taku Kouro et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2022)
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Alexander Dimitri et al.
MOLECULAR CANCER (2022)
Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors
Yibo Yin et al.
MOLECULAR THERAPY (2022)
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
Changsong Qi et al.
NATURE MEDICINE (2022)
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
Vivek Narayan et al.
NATURE MEDICINE (2022)
Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
Pouya Safarzadeh Kozani et al.
FRONTIERS IN IMMUNOLOGY (2022)
Dysregulation of Survivin-Targeting microRNAs in Autoimmune Diseases: New Perspectives for Novel Therapies
Navid Shomali et al.
FRONTIERS IN IMMUNOLOGY (2022)
CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities
Lionel A. Kankeu Fonkoua et al.
MOLECULAR THERAPY-ONCOLYTICS (2022)
Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
Diana Gumber et al.
EBIOMEDICINE (2022)
The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme
Amin Daei Sorkhabi et al.
FRONTIERS IN ONCOLOGY (2022)
Survivin; a novel therapeutic target that correlates with survival of autoreactive T lymphocytes obtained from patients with ankylosing spondylitis
Navid Shomali et al.
GENE (2022)
Silencing of SiX-4 enhances the chemosensitivity of melanoma cells to Cisplatin
Aysan Fallah Vazirabad et al.
PATHOLOGY RESEARCH AND PRACTICE (2022)
Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
Ali Keshavarz et al.
STEM CELL RESEARCH & THERAPY (2022)
Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
Tadesse Asmamaw Dejenie et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)
Targeting HER2 expression in cancer: New drugs and new indications
Semir Vranic et al.
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES (2021)
NEO100 enables brain delivery of blood-brain barrier impermeable therapeutics
Weijun Wang et al.
NEURO-ONCOLOGY (2021)
Updated data from alloSHRINK phase I first-inhuman study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC.
Hans Prenen et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Counteracting CAR T cell dysfunction
Mansour Poorebrahim et al.
ONCOGENE (2021)
Deletion of Cbl-b inhibits CD8+ T-cell exhaustion and promotes CAR T-cell function
Jitendra Kumar et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Optimization of metabolism to improve efficacy during CAR-T cell manufacturing
Meng Zhang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2021)
CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy
Alba Rodriguez-Garcia et al.
NATURE COMMUNICATIONS (2021)
BAY 60-6583 Enhances the Antitumor Function of Chimeric Antigen Receptor-Modified T Cells Independent of the Adenosine A2b Receptor
Jiaxing Tang et al.
FRONTIERS IN PHARMACOLOGY (2021)
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
Laura Castelletti et al.
BIOMARKER RESEARCH (2021)
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment
Guangna Liu et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
Evan W. Weber et al.
SCIENCE (2021)
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Zhenguang Wang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China: A phase I trial.
Zhongwei Zhao et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin
Nengzhi Pang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis
Nicholas A. Vitanza et al.
NATURE MEDICINE (2021)
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab
Prasad S. Adusumilli et al.
CANCER DISCOVERY (2021)
Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy
Xianhui Chen et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors
Bruno L. Cadilha et al.
SCIENCE ADVANCES (2021)
Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis
Wen Lei et al.
CANCERS (2021)
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours
Stefanie Lesch et al.
NATURE BIOMEDICAL ENGINEERING (2021)
Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control
Ian C. Miller et al.
NATURE BIOMEDICAL ENGINEERING (2021)
Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model
Juan Fu et al.
JOURNAL OF VETERINARY MEDICAL SCIENCE (2021)
Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors
Paris Kosti et al.
CELL REPORTS MEDICINE (2021)
Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer
Cong Chen et al.
ONCOIMMUNOLOGY (2021)
Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma
Xin Tang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
IFN-γ surmounts PD-L1/PD1 inhibition to CAR-T cell therapy by upregulating ICAM-1 on tumor cells
E. Dong et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases
Steven C. Katz et al.
CANCER GENE THERAPY (2020)
The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors
Changwen Deng et al.
MOLECULAR THERAPY (2020)
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Transforming growth factor ? (TGF-?) receptor signaling regulates kinase networks and phosphatidylinositol metabolism during T-cell activation
Richard T. Cattley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies
Valeska Moentenich et al.
ONCOLOGY LETTERS (2020)
Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
Ching-Yao Yang et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma
Laura K. Donovan et al.
NATURE MEDICINE (2020)
Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity
Livingstone Fultang et al.
BLOOD (2020)
CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
Alba Rodriguez-Garcia et al.
FRONTIERS IN IMMUNOLOGY (2020)
Lactate Dehydrogenase A Depletion Alters MyC-CaP Tumor Metabolism, Microenvironment, and CAR T Cell Therapy
Mayuresh M. Mane et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
Bassel Nazha et al.
FRONTIERS IN ONCOLOGY (2020)
Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo
Sarah A. Richman et al.
MOLECULAR THERAPY (2020)
HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery
Steven C. Katz et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Manipulation of Glucose Availability to Boost Cancer Immunotherapies
Federica Marchesi et al.
CANCERS (2020)
Engineering better chimeric antigen receptor T cells
Hao Zhang et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)
Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing
Qibin Liao et al.
BIOMARKER RESEARCH (2020)
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Negar Hosseinkhani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy
Ramon I. Klein Geltink et al.
NATURE METABOLISM (2020)
Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models
Diyuan Qin et al.
ONCOIMMUNOLOGY (2020)
Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer
Hua Jiang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer
Hua Jiang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells
Hongwei Du et al.
CANCER CELL (2019)
Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer
Bing-Lan Zhang et al.
HUMAN GENE THERAPY (2019)
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma
Stephanie L. Goff et al.
JOURNAL OF IMMUNOTHERAPY (2019)
NR4A transcription factors limit CAR T cell function in solid tumours
Joyce Chen et al.
NATURE (2019)
IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype
Darya Alizadeh et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Cancer-cell-secreted CXCL11 promoted CD8+ T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC
Qun Gao et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: Preliminary results with cyclophosphamide (Cy) ± fludarabine (Flu) lymphodepletion (LD).
Carlos Roberto Becerra et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma.
Xianbao Zhan et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.
Prasad S. Adusumilli et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma
Xiuqi Wu et al.
MOLECULAR THERAPY (2019)
CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies
Lynsey M. Whilding et al.
CANCERS (2019)
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers
Andrew R. Haas et al.
MOLECULAR THERAPY (2019)
Gene editing for immune cell therapies
Stefanie R. Bailey et al.
NATURE BIOTECHNOLOGY (2019)
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
Bryan D. Choi et al.
NATURE BIOTECHNOLOGY (2019)
Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma
Jing Cui et al.
NEURO-ONCOLOGY (2019)
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Katrin Mestermann et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy
Yogindra Vedvyas et al.
SCIENTIFIC REPORTS (2019)
MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
Livingstone Fultang et al.
EBIOMEDICINE (2019)
35O Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer
Y Lin et al.
ANNALS OF ONCOLOGY (2019)
Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding
Nandini Mondal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
CXCR1-or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
Linchun Jin et al.
NATURE COMMUNICATIONS (2019)
Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities
Bhagirathbhai R. Dholaria et al.
BIODRUGS (2019)
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Rosalie M. Sterner et al.
BLOOD (2019)
Teaching an old dog new tricks: next-generation CAR T cells
Nicholas Tokarew et al.
BRITISH JOURNAL OF CANCER (2019)
CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
Wanghong Hu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors
Yong Gu Lee et al.
CANCER RESEARCH (2019)
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
Robbie G. Majzner et al.
CLINICAL CANCER RESEARCH (2019)
The First Step in Adoptive Cell Immunotherapeutics: Assuring Cell Delivery via Glycoengineering
Robert Sackstein
FRONTIERS IN IMMUNOLOGY (2019)
Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety-A Systematic Review with Meta-Analysis
Wen-Liang Yu et al.
CANCERS (2019)
Chimeric antigen receptors designed to overcome transforming growth factor-β-mediated repression in the adoptive T-cell therapy of solid tumors
Jordan Hartley et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2019)
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations
Robert Weinkove et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2019)
In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy
Jorge Garcia Borrega et al.
HEMASPHERE (2019)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
CD70, a novel target of CAR T-cell therapy for gliomas
Linchun Jin et al.
NEURO-ONCOLOGY (2018)
Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
Kaichao Feng et al.
PROTEIN & CELL (2018)
Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model
Paola Bocca et al.
ONCOIMMUNOLOGY (2018)
mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting
Jason J. Lohmueller et al.
ONCOIMMUNOLOGY (2018)
Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety
Leena Halim et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells
In-Young Jung et al.
CANCER RESEARCH (2018)
Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
Jang Hwan Cho et al.
CELL (2018)
Functions of NKG2D in CD8+ T cells: an opportunity for immunotherapy
Kushal Prajapati et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
Gregory L. Beatty et al.
GASTROENTEROLOGY (2018)
The expansion of targetable biomarkers for CAR T cell therapy
Michelle H. Townsend et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Metabolic Barriers to T Cell Function in Tumors
Ayaka Sugiura et al.
JOURNAL OF IMMUNOLOGY (2018)
Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma
Christine E. Brown et al.
MOLECULAR THERAPY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
EEG findings in CAR T-cell therapy-related encephalopathy
Aline Herlopian et al.
NEUROLOGY (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner
Romy Loschinski et al.
Oncotarget (2018)
Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager
Anna Wing et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines
Edmund K. Moon et al.
ONCOIMMUNOLOGY (2018)
Immune oncology, immune responsiveness and the theory of everything
Tolga Turan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy
Yanfen Liu et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Joseph A. Fraietta et al.
NATURE (2018)
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
Alexander I. Salter et al.
SCIENCE SIGNALING (2018)
Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
Xingliang Guo et al.
FRONTIERS IN PHARMACOLOGY (2018)
CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge
Sonia Guedan et al.
FRONTIERS IN IMMUNOLOGY (2018)
Oncolytic viruses as engineering platforms for combination immunotherapy
Kwame Twumasi-Boateng et al.
NATURE REVIEWS CANCER (2018)
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses
Keisuke Watanabe et al.
JCI INSIGHT (2018)
Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers
Yelei Guo et al.
CLINICAL CANCER RESEARCH (2018)
TGF-β-responsive CAR-T cells promote anti-tumor immune function
Andrew J. Hou et al.
BIOENGINEERING & TRANSLATIONAL MEDICINE (2018)
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
A. Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms
M. Ruella et al.
LEUKEMIA (2017)
Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors
R. Monjezi et al.
LEUKEMIA (2017)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer
Somala Mohammed et al.
MOLECULAR THERAPY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma
Khun Visith Keu et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells
Mohanraj Ramachandran et al.
SEMINARS IN CANCER BIOLOGY (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
An oxygen sensitive self-decision making engineered CAR T-cell
Alexandre Juillerat et al.
SCIENTIFIC REPORTS (2017)
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Oladapo O. Yeku et al.
SCIENTIFIC REPORTS (2017)
Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
Julia Tchou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Pl3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells
Jacob S. Bowers et al.
FRONTIERS IN IMMUNOLOGY (2017)
Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
Hamid R. Mirzaei et al.
FRONTIERS IN IMMUNOLOGY (2017)
Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
Congcong Zhang et al.
FRONTIERS IN IMMUNOLOGY (2017)
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial
Nabil Ahmed et al.
JAMA ONCOLOGY (2017)
CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth
Vita Golubovskaya et al.
CANCERS (2017)
The composition of T-cell subsets are altered in the burn wound early after injury
Meenakshi Rani et al.
PLOS ONE (2017)
A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+hepatocellular carcinoma (r/r GPC3+HCC).
Bo Zhai et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma.
Meenakshi Hegde et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Si Li et al.
CLINICAL CANCER RESEARCH (2017)
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors
Joerg Felsberg et al.
CLINICAL CANCER RESEARCH (2017)
Migrating into the Tumor: a Roadmap for T Cells
Lieke L. van der Woude et al.
TRENDS IN CANCER (2017)
HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer
Tristan A. Barnes et al.
BRITISH JOURNAL OF CANCER (2017)
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors
Kiyonori Tanoue et al.
CANCER RESEARCH (2017)
Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies
Kevin A. Hay et al.
DRUGS (2017)
The Principles of Engineering Immune Cells to Treat Cancer
Wendell A. Lim et al.
CELL (2017)
Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity
Maarten A. Ligtenberg et al.
JOURNAL OF IMMUNOLOGY (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer
Moritz Rapp et al.
ONCOIMMUNOLOGY (2016)
Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells - a completed study overview
Cor H. J. Lamers et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2016)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
Xiaojun Liu et al.
CANCER RESEARCH (2016)
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Kole T. Roybal et al.
CELL (2016)
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
Roger Geiger et al.
CELL (2016)
B7-H3 Overexpression Predicts Poor Survival of Cancer Patients: A Meta-Analysis
Zhimeng Ye et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2016)
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
Elodie Picarda et al.
CLINICAL CANCER RESEARCH (2016)
The urgent need to recover MHC class I in cancers for effective immunotherapy
Federico Garrido et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia
Nathan Singh et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)
Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells
David F. Stroncek et al.
CYTOTHERAPY (2016)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
Omkar U. Kawalekar et al.
IMMUNITY (2016)
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
Avery D. Posey et al.
IMMUNITY (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Hanren Dai et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma
Giedre Krenciute et al.
MOLECULAR THERAPY (2016)
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Versatile strategy for controlling the specificity and activity of engineered T cells
Jennifer S. Y. Ma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
David T. Rodgers et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
Richard P. Junghans et al.
PROSTATE (2016)
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
Fengtao You et al.
SCIENCE CHINA-LIFE SCIENCES (2016)
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
M. Cartellieri et al.
BLOOD CANCER JOURNAL (2016)
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
Benjamin V. Park et al.
CANCER DISCOVERY (2016)
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
Eloah Rabello Suarez et al.
ONCOTARGET (2016)
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Hanren Dai et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
Kheng Newick et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
Adrienne H. Long et al.
CANCER IMMUNOLOGY RESEARCH (2016)
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
Eugenia Zah et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19
Mattias Carlsten et al.
FRONTIERS IN IMMUNOLOGY (2016)
Fine-tuning the CAR spacer improves T-cell potency
Norihiro Watanabe et al.
ONCOIMMUNOLOGY (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
A quantum leap in cancer vaccines?
Eli Gilboa
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient
Imran Siddiqui et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function
David M. Barrett et al.
BLOOD (2016)
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
Luana Schito et al.
TRENDS IN CANCER (2016)
Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity
Yanhong Wu et al.
BMC CANCER (2015)
Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM
Zhenling Deng et al.
BMC IMMUNOLOGY (2015)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
Multiplex Genome-Edited T-cell Manufacturing Platform for Off-the-Shelf Adoptive T-cell Immunotherapies
Laurent Poirot et al.
CANCER RESEARCH (2015)
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang et al.
CELL (2015)
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Christine E. Brown et al.
CLINICAL CANCER RESEARCH (2015)
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
Steven C. Katz et al.
CLINICAL CANCER RESEARCH (2015)
Smart CARs engineered for cancer immunotherapy
Saul J. Priceman et al.
CURRENT OPINION IN ONCOLOGY (2015)
Redirection of Genetically Engineered CAR-T Cells Using Bifunctional Small Molecules
Min Soo Kim et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression
Kevin J. Curran et al.
MOLECULAR THERAPY (2015)
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Ignazio Caruana et al.
NATURE MEDICINE (2015)
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Adrienne H. Long et al.
NATURE MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
Chia-Yung Wu et al.
SCIENCE (2015)
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma
Laura A. Johnson et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
Nikolaos Patsoukis et al.
NATURE COMMUNICATIONS (2015)
Fine-tuning Tumor Immunity with Integrin Trans-regulation
Joseph M. Cantor et al.
CANCER IMMUNOLOGY RESEARCH (2015)
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Mythili Koneru et al.
ONCOIMMUNOLOGY (2015)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins et al.
CLINICAL CANCER RESEARCH (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
CAR T Cells for Solid Tumors Armed and Ready to Go?
Sunitha Kakarla et al.
CANCER JOURNAL (2014)
T Lymphocytes Expressing a CD16 Signaling Receptor Exert Antibody-Dependent Cancer Cell Killing
Ko Kudo et al.
CANCER RESEARCH (2014)
Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor-Modified T Cells in Solid Tumors
Nobuhiro Nishio et al.
CANCER RESEARCH (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
Prasad S. Adusumilli et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
Liang-Chuan S. Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments anc parallelisms with other tissues
Eva Van Overmeire et al.
FRONTIERS IN IMMUNOLOGY (2014)
T cell responses: naive to memory and everything in between
Nathan D. Pennock et al.
ADVANCES IN PHYSIOLOGY EDUCATION (2013)
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Liza B. John et al.
CLINICAL CANCER RESEARCH (2013)
Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery
Xinping Fu et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Preclinical In Vivo Modeling of Cytokine Release Syndrome Induced by ErbB-Retargeted Human T Cells: Identifying a Window of Therapeutic Opportunity?
Sjoukje J. C. van der Stegen et al.
JOURNAL OF IMMUNOLOGY (2013)
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Richard A. Morgan et al.
JOURNAL OF IMMUNOTHERAPY (2013)
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
Cor H. J. Lamers et al.
MOLECULAR THERAPY (2013)
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
Christopher C. Kloss et al.
NATURE BIOTECHNOLOGY (2013)
PD-1-and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
Victor D. Fedorov et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain et al.
CANCER DISCOVERY (2013)
Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
Evripidis Lanitis et al.
CANCER IMMUNOLOGY RESEARCH (2013)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Marcela V. Maus et al.
CANCER IMMUNOLOGY RESEARCH (2013)
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Zakaria Grada et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2013)
Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells
Markus Chmielewski et al.
FRONTIERS IN IMMUNOLOGY (2013)
Role of the EpCAM (CD326) in prostate cancer metastasis and progression
Jie Ni et al.
CANCER AND METASTASIS REVIEWS (2012)
PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines
Weiyi Peng et al.
CANCER RESEARCH (2012)
Local Delivery of Interleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
Dhanalakshmi Chinnasamy et al.
CLINICAL CANCER RESEARCH (2012)
Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
Koji Tamada et al.
CLINICAL CANCER RESEARCH (2012)
Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
Scott Wilkie et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor
Megan E. Prosser et al.
MOLECULAR IMMUNOLOGY (2012)
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter et al.
NATURE MEDICINE (2012)
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
Xiuli Wang et al.
BLOOD (2011)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
M. J. M. Gooden et al.
BRITISH JOURNAL OF CANCER (2011)
Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control
Michelle Hong et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2011)
Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas
Olivera J. Finn et al.
IMMUNOLOGIC RESEARCH (2011)
Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4
Scott Wilkie et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell-mediated Tumor Eradication
Xiao-Song Zhong et al.
MOLECULAR THERAPY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers
Michael C. Haffner et al.
HUMAN PATHOLOGY (2009)
Fludarabine Modulates Immune Response and Extends In Vivo Survival of Adoptively Transferred CD8 T Cells in Patients with Metastatic Melanoma
Herschel Wallen et al.
PLOS ONE (2009)
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
Carmine Carpenito et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: A tissue microarray analysis of 4,387 tissue samples
Daniel Baumhoer et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Hypoxia-Adenosinergic Immunosuppression: Tumor Protection by T Regulatory Cells and Cancerous Tissue Hypoxia
Michail V. Sitkovsky et al.
CLINICAL CANCER RESEARCH (2008)
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin A. Pule et al.
NATURE MEDICINE (2008)
CC-chemokine ligand 17 gene therapy induces tumor regression through augmentation of tumor-infiltrating immune cells in a murine model of preexisting CT26 colon carcinoma
Naoko Kanagawa et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells
Christine E. Brown et al.
JOURNAL OF IMMUNOLOGY (2007)
Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma
Julie R. Park et al.
MOLECULAR THERAPY (2007)
Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat
Mads A. Tarp et al.
GLYCOBIOLOGY (2007)
Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy
Monica Huszar et al.
HUMAN PATHOLOGY (2006)
Allogeneic and autologous melanoma vaccines:: Where have we been and where are we going?
VK Sondak et al.
CLINICAL CANCER RESEARCH (2006)
Molecular mechanisms of cell recruitment to inflammatory sites: general and tissue-specific pathways
T Garrood et al.
RHEUMATOLOGY (2006)
Expression patterns of potential therapeutic targets in prostate cancer
T Zellweger et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain
HM Finney et al.
JOURNAL OF IMMUNOLOGY (2004)
Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine
EC Hsueh et al.
SEMINARS IN CANCER BIOLOGY (2003)
Chemokines, chemokine receptors and adhesion molecules on different human endothelia: discriminating the tissue-specific functions that affect leucocyte migration
P Hillyer et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2003)
Paxillin binding to the α4 integrin subunit stimulates LFA-1 (integrin αLβ2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2
DM Rose et al.
JOURNAL OF IMMUNOLOGY (2003)
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2
MH Kershaw et al.
HUMAN GENE THERAPY (2002)
Hypoxia and oxidative stress in breast cancer - Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer
NS Brown et al.
BREAST CANCER RESEARCH (2001)
分享论文
